Company Celcuity Inc.

Equities

CELC

US15102K1007

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
16.83 ^USD	-3.00%		-4.75%	+15.51%

Mar. 29	Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement	CI
Mar. 28	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Number of employees: 55

Managers	Title	Age	Since
Lance Laing FOU	Founder	62	11-12-31
Brian Sullivan CEO	Chief Executive Officer	62	11-12-31
Vicky Hahne DFI	Director of Finance/CFO	57	17-06-30
Pratima Nayak CTO	Chief Tech/Sci/R&D Officer	-	-
John R. MacDonald CTO	Chief Tech/Sci/R&D Officer	-	21-04-07
Nadene Zack CTO	Chief Tech/Sci/R&D Officer	-	-
Igor Gorbatchevsky CTO	Chief Tech/Sci/R&D Officer	-	21-06-08
Bernhard Lampert PRN	Corporate Officer/Principal	-	21-04-07
Mark Mannebach LAW	General Counsel	-	22-03-31
Eldon Mayer PRN	Corporate Officer/Principal	62	Feb. 19

Members of the board	Title	Age	Since
Brian Sullivan CEO	Chief Executive Officer	62	11-12-31
Richard Nigon BRD	Director/Board Member	76	16-12-31
David Dalvey BRD	Director/Board Member	65	14-01-31
Leo Furcht BRD	Director/Board Member	77	19-05-15
Richard Buller BRD	Director/Board Member	74	19-12-02
Lance Laing FOU	Founder	62	11-12-31
Polly Murphy BRD	Director/Board Member	59	22-09-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	30,453,120	24,600,156 ( 80.78 %)	0	80.78 %

Name	Equities	%	Valuation
Brian Sullivan 9.906 %	3,016,643	9.906 %	48 M $
Soleus Capital Management LP (Investment Management) 8.616 %	2,623,890	8.616 %	41 M $
Morgan Stanley Investment Management, Inc. 7.208 %	2,195,179	7.208 %	35 M $
Soleus Capital Management LP 7.157 %	2,179,481	7.157 %	34 M $
Venrock Associates 6.192 %	1,885,538	6.192 %	30 M $
Commodore Capital LP 5.762 %	1,754,704	5.762 %	28 M $
Perceptive Advisors LLC 4.864 %	1,481,300	4.864 %	23 M $
NEA Management Co. LLC 4.105 %	1,250,001	4.105 %	20 M $
Lance Laing 4.105 %	1,250,000	4.105 %	20 M $
BlackRock Advisors LLC 3.487 %	1,061,956	3.487 %	17 M $

Name	Equities	%	Valuation
RA Capital Management LP 16.21 %	181,739	16.21 %	3 M $
Commodore Capital LP 3.795 %	42,532	3.795 %	670 730 $

Celcuity, Inc.

16305 36th Avenue North Suite 100

55446, Minneapolis

http://www.celcuity.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.83 USD

Average target price

29.5 USD

Spread / Average Target

+75.28%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CELCUITY INC.	+15.51%	513M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	0.00%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.73%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs